Gerard Harty

Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options

Marcel F. Jonker, Bas Donkers, Lucas Goossens et al. · Medical Decision Making · 2020 · 40 citations · Full text

Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England

Robert Hettle, Gerard Harty, Schiffon L. Wong · Journal of Medical Economics · 2018 · 38 citations · Full text

Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work

Gerard Harty, James Jarrett, Mireia Jofre‐Bonet · Applied Health Economics and Health Policy · 2018 · 19 citations · Full text

Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands

Renée Michels, Maria de Fransesco, Koshu Mahajan et al. · Applied Health Economics and Health Policy · 2019 · 18 citations · Full text

Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: <i>post hoc</i> analysis of subgroups with and without prior disease-modifying drug treatment

Patrick Vermersch, Andrew Galazka, Fernando Dangond et al. · Current Medical Research and Opinion · 2020 · 13 citations · Full text